Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019; 18: 96-103
Случай гепатоспленической γδ Т-клеточной лимфомы у ребенка
https://doi.org/10.24287/1726-1708-2019-18-1-96-103Аннотация
Гепатоспленическая Т-клеточная лимфома (ГТКЛ) - редкая, агрессивно протекающая периферическая Т-клеточная лимфома, характеризующаяся пролиферацией злокачественных ав или γδ Т-лимфоцитов в печени, селезенке, костном мозге. В статье представлен анализ литературных данных и разбор клинического случая гепатоспленической γδ Т-клеточной лимфомы у ребенка 4 лет. Родители пациента дали согласие на использование информации о нем, в том числе фотографий, в научных исследованиях и публикациях.
Список литературы
1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016; 127:2375-2390. DOI: https://doi.org/10.1182/blood-2016-01-643569
2. Gaulard P., Marolleau J.P., Le Couedic J.P., Henni T., Gourdin M.F., Divine M., et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma-delta. Blood 1990; 75 (11): 2213-9.
3. Armitage J.O. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 2017; 92: 706-15.
4. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood 1994; 84: 1361-92.
5. Suarez F., Wlodarska I., Rigal-Hugu-et F., Mempel M., Martin-Garcia N., Farcet J.P. Hepatosplenic alpha-beta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gamma-delta hepatosplen-ic T-cell lymphoma. Am J Surg Pathol 2000; 24: 1027-32.
6. Gaulard P., Jaffe E.S., Krenacs L., Macon W.R. Hepatosplenic T-cell lymphoma. In: Swerdlow S.H, Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2017; 381-2.
7. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.
8. Ferreri A.J., Govi S., Pileri S.A. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 2012 Aug; 83 (2): 283-92. DOI: 10.1016/j.cri-trevonc.2011.10.001. Epub 2011 Nov 1
9. Thai A., Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-22.
10. Kotlgar D.S. A Systematic Review of Factors That Contribute of Hepatosplenic T-cell Lymphoma in Patients with Inflam. Borel Disease.
11. Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7.
12. Ochenrider M.G., Patterson D.J., Abou-lafia D.M. Hepatosplenic T-cell Lymphoma in a Young Man With Crohn's Disease: Case Report and Literature Review. Clinical Lymphoma, Myeloma & Leukemia 2010; 10 (2): 144-8.
13. Weidmann E. Hepatosplenic T-cell lym- 21. phoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14 (6): 991-7.
14. Cooke C.B., Krenacs L., Stetler- 22. Stevenson M., Greiner T.C., Raffeld M., Kingma D.W. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.
15. Florena A.M., Tripodo C., Porcasi R., Ingrao S., Fadda M.R., De Cantis S. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk Lymphoma 2006; 47 (1): 49-57.
16. Belhadj K., Reyes F., Farcet J.P., Tilly H., Bastard C., Angonin R. Hepatosplenic gamma delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003; 102: 4261-9.
17. Macon W.R., Levy N.B., Kurtin P.J., Salhany K.E., Elkhalifa M.Y., Casey T.T. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Sur Pathol 26. 2001; 25 (3): 285-96.
18. Przybylski G.K., Wu H., Macon W.R., Finan J., Leonard D.G., Felgar R.E. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T-cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000; 2 (1): 11-9.
19. Wlodarska I., Martin-Garcia N., Ach-ten R., De Wolf-Peeters C., Pauwels P., Tulliez M. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes, chromosomes & cancer 2002; 33: 243-51.
20. McKinney M., Moffitt A.B., Gau-lard P., Travert M., De Leval L., Nicolae A. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discovery 2017; 7 (4): 369-79.
21. Calvaruso M., Gulino A., Buffa S., Guarnotta C., Franco G., Cacciatore M. Challenges and new prospects in hepat-osplenic yS T-cell lymphoma. Leukemia & Lymphoma 2014; 55 (11): 2457-65.
22. Weidmann E. Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991-7.
23. Falchook G.S., Vega F., Dang N.H., Samaniego F., Rodriguez M.A., Cham-plin R.E. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20: 1080-5.
24. Jaeger G., Bauer F., Brezinschek R., Beham-Schmid C., Mannhalter C., Neu-meister P. Hepatosplenic gammadelta Tcell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008; 19 (5): 1025-6.
25. Koenecke C., Czeloth N., Bubke A., Schmitz S., Kissenpfennig A., Malis-sen B. Alloantigen-specific de novo-in-duced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009; 39 (11): 3091-6.
26. Martinet L., Fleury-Cappellesso S., Gadelorge M., Dietrich G., Bourin P., Fournie J.-J. A regulatory cross-talk between gamma delta T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009; 39 (3): 752-62.
Pediatric Hematology/Oncology and Immunopathology. 2019; 18: 96-103
Hepatosplenic γδ T-cell lymphoma in a 4 years old child
https://doi.org/10.24287/1726-1708-2019-18-1-96-103Abstract
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and clinically aggressive type of T-cell lymphoma that characterized by proliferation in the liver, spleen and bone marrow. The article presents analytical review of literature and the clinical case of γδ HSTCL in 4 years old child. Patient's parents agreed to use personal dats and photos in research and publications.
References
1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016; 127:2375-2390. DOI: https://doi.org/10.1182/blood-2016-01-643569
2. Gaulard P., Marolleau J.P., Le Couedic J.P., Henni T., Gourdin M.F., Divine M., et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma-delta. Blood 1990; 75 (11): 2213-9.
3. Armitage J.O. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 2017; 92: 706-15.
4. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood 1994; 84: 1361-92.
5. Suarez F., Wlodarska I., Rigal-Hugu-et F., Mempel M., Martin-Garcia N., Farcet J.P. Hepatosplenic alpha-beta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gamma-delta hepatosplen-ic T-cell lymphoma. Am J Surg Pathol 2000; 24: 1027-32.
6. Gaulard P., Jaffe E.S., Krenacs L., Macon W.R. Hepatosplenic T-cell lymphoma. In: Swerdlow S.H, Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2017; 381-2.
7. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.
8. Ferreri A.J., Govi S., Pileri S.A. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 2012 Aug; 83 (2): 283-92. DOI: 10.1016/j.cri-trevonc.2011.10.001. Epub 2011 Nov 1
9. Thai A., Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-22.
10. Kotlgar D.S. A Systematic Review of Factors That Contribute of Hepatosplenic T-cell Lymphoma in Patients with Inflam. Borel Disease.
11. Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7.
12. Ochenrider M.G., Patterson D.J., Abou-lafia D.M. Hepatosplenic T-cell Lymphoma in a Young Man With Crohn's Disease: Case Report and Literature Review. Clinical Lymphoma, Myeloma & Leukemia 2010; 10 (2): 144-8.
13. Weidmann E. Hepatosplenic T-cell lym- 21. phoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14 (6): 991-7.
14. Cooke C.B., Krenacs L., Stetler- 22. Stevenson M., Greiner T.C., Raffeld M., Kingma D.W. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.
15. Florena A.M., Tripodo C., Porcasi R., Ingrao S., Fadda M.R., De Cantis S. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk Lymphoma 2006; 47 (1): 49-57.
16. Belhadj K., Reyes F., Farcet J.P., Tilly H., Bastard C., Angonin R. Hepatosplenic gamma delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003; 102: 4261-9.
17. Macon W.R., Levy N.B., Kurtin P.J., Salhany K.E., Elkhalifa M.Y., Casey T.T. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Sur Pathol 26. 2001; 25 (3): 285-96.
18. Przybylski G.K., Wu H., Macon W.R., Finan J., Leonard D.G., Felgar R.E. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T-cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000; 2 (1): 11-9.
19. Wlodarska I., Martin-Garcia N., Ach-ten R., De Wolf-Peeters C., Pauwels P., Tulliez M. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes, chromosomes & cancer 2002; 33: 243-51.
20. McKinney M., Moffitt A.B., Gau-lard P., Travert M., De Leval L., Nicolae A. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discovery 2017; 7 (4): 369-79.
21. Calvaruso M., Gulino A., Buffa S., Guarnotta C., Franco G., Cacciatore M. Challenges and new prospects in hepat-osplenic yS T-cell lymphoma. Leukemia & Lymphoma 2014; 55 (11): 2457-65.
22. Weidmann E. Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991-7.
23. Falchook G.S., Vega F., Dang N.H., Samaniego F., Rodriguez M.A., Cham-plin R.E. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20: 1080-5.
24. Jaeger G., Bauer F., Brezinschek R., Beham-Schmid C., Mannhalter C., Neu-meister P. Hepatosplenic gammadelta Tcell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008; 19 (5): 1025-6.
25. Koenecke C., Czeloth N., Bubke A., Schmitz S., Kissenpfennig A., Malis-sen B. Alloantigen-specific de novo-in-duced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009; 39 (11): 3091-6.
26. Martinet L., Fleury-Cappellesso S., Gadelorge M., Dietrich G., Bourin P., Fournie J.-J. A regulatory cross-talk between gamma delta T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009; 39 (3): 752-62.
